<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155193</url>
  </required_header>
  <id_info>
    <org_study_id>P10-410</org_study_id>
    <nct_id>NCT01155193</nct_id>
  </id_info>
  <brief_title>Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany</brief_title>
  <official_title>Prospective, Non-interventional Observation Study for the Use of Palivizumab in High-risk Children in Germany- SYNAGIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SYNAGIS Registry was carried out in order to gather comprehensive real-world data on the
      use of palivizumab in children at high risk for serious respiratory syncytial virus (RSV)
      disease. This registry was designed as a post-marketing observational study, and conducted
      with the aim of collecting data on palivizumab administration, the risk factors for
      complicated RSV disease, frequency of hospitalizations, and drug adherence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant included in this study was observed during his/her palivizumab prophylaxis
      during the prevailing RSV season. According to the requirements for non-interventional or
      observational studies, no diagnostic or monitoring procedures were applied to the
      participants included in the study other than those which would ordinarily be applied in the
      course of the individual therapeutic strategy. Only data which were part of routine medical
      care were collected.

      Data collection was conducted initially in season 2002/2003 using paper-based case report
      forms (CRFs); beginning in season 2008/2009 a protected internet-based data entry platform
      was used. Both the paper-based CRFs and the electronic system were subject to changes during
      the whole time of the registry.

      Data collection for registry seasons 2002/2003 - 2006/2007 was conducted by use of
      paper-based CRFs and hospitalization forms. Corresponding results were published in 2011 and
      are hence depicted together and reported here as a separate reporting group.

      Registry seasons 2007/2008 and 2008/2009 were considered transitional years in the process of
      switching the type of data collection to an electronic CRF (eCRF) system. Although data
      collection of registry 2007/2008 was still paper-based, it was not included in the original
      publication and hence, results are reported separately. In season 2008/2009 the mode of data
      collection was switched from paper-based CRFs to an eCRF system, however, several physicians
      still used the paper-based CRFs for documentation. In order to use all documentations and
      lose as few data as possible, results for 2008/2009 are based on a combination of paper-based
      CRF and eCRF data. Hence, it was decided to keep the results for 08/09 separate from the
      depiction of the homogenous, eCRF-based results of the following seasons.

      Data collection for registry 09/10 - 15/16 was implemented by an eCRF system. Corresponding
      results are therefore depicted together in one reporting group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2002</start_date>
  <completion_date type="Actual">July 31, 2016</completion_date>
  <primary_completion_date type="Actual">July 31, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of Participants With RSV-associated Hospitalization</measure>
    <time_frame>During RSV season (September to June) from 2002 to 2016</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis Documented at Hospital Discharge in Registries 02/03 - 06/07 and 07/08</measure>
    <time_frame>During RSV season (September to June) from 2002 to 2008</time_frame>
    <description>Hospitalization due to RSV was documented on a separate hospitalization form. The data below represent the number of hospitalizations documented on forms; some participants may have had more than one hospitalization. Multiple entries for discharge diagnosis were possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis Documented at Hospital Discharge in Registry 08/09 and 09/10 - 15/16</measure>
    <time_frame>During RSV season (September to June) from 2008 to 2016</time_frame>
    <description>In the season 2008/09, the eCRF system for data collection was introduced. Hospitalization due to RSV infection was documented on a separate hospitalization form in the electronic case report form (eCRF). Physicians were asked to specify a primary diagnosis at hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Complications During Hospitalization</measure>
    <time_frame>During RSV season (September to June) from 2002 to 2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental Cooperation in Registries 02/03 - 06/07 and 07/08</measure>
    <time_frame>During RSV season (September to June) from 2002 to 2008</time_frame>
    <description>Cooperation of parents with the prophylaxis regimen was categorized as very good, good, moderate, bad or very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental Cooperation for Registry 08/09 and 09/10 - 15/16</measure>
    <time_frame>During RSV season (September to June) from 2008 to 2016</time_frame>
    <description>Cooperation of parents with the prophylaxis regimen was evaluated per injection in registry 08/09 and 09/10 - 15/16. The categories for cooperation ratings were changed to good, satisfying, or bad:
Good: all palivizumab doses could be administered as planned; Satisfying: a single palivizumab dose was missed by the parents; Bad: more than one palivizumab doses was missed by the parents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Palivizumab Injections</measure>
    <time_frame>During RSV season (September to June) from 2002 to 2016</time_frame>
    <description>The mean number of palivizumab injections per participant, per season.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30804</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Palivizumab</arm_group_label>
    <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care pediatricians from hospital outpatient facilities and neonatologists from
        inpatient facilities were invited to participate in this study and enrolled subjects into
        the registry at their discretion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children born at 35 weeks of gestation or less and less than 6 months of age at the
             onset of the Respiratory syncytial virus season

          -  Children less than 2 years of age and requiring treatment for bronchopulmonary
             dysplasia within the last 6 months.

          -  Children less than 2 years of age and with hemodynamically significant congenital
             heart disease.

        Exclusion Criteria:

          -  Children with known hypersensitivity to palivizumab or any component of the
             formulation, or other humanized monoclonal antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Bloch, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Deutschland GmbH &amp; Co. KG, Medical Department</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41516</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <results_first_submitted>July 12, 2017</results_first_submitted>
  <results_first_submitted_qc>February 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Pre-term infants</keyword>
  <keyword>Congenital heart disease</keyword>
  <keyword>Infection</keyword>
  <keyword>Respiratory syncytial virus</keyword>
  <keyword>Bronchopulmonary dysplasia (BPD)</keyword>
  <keyword>Chronic lung disease (CLD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pre-term infants and children under 24 months with high-risk for respiratory syncytial virus (RSV) were enrolled between September 01 and June 30 during each RSV season from 2002 to 2016. The registry was conducted in Germany.</recruitment_details>
      <pre_assignment_details>Results were subdivided into four parts due to procedural changes including changes in the methods of study data reporting during the conduct of the study:
Registry 02/03 – 06/07
Registry 07/08
Registry 08/09
Registry 09/10 – 15/16</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Palivizumab Registry 02/03 – 06/07</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 until 30 June 2007.</description>
        </group>
        <group group_id="P2">
          <title>Palivizumab Registry 07/08</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
        </group>
        <group group_id="P3">
          <title>Palivizumab Registry 08/09</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2008 to 30 June 2009.</description>
        </group>
        <group group_id="P4">
          <title>Palivizumab Registry 09/10 – 15/16</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10924"/>
                <participants group_id="P2" count="3818"/>
                <participants group_id="P3" count="2260"/>
                <participants group_id="P4" count="13802"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10686">Evaluable population (participants treated between 01 September and 01 May of the following year)</participants>
                <participants group_id="P2" count="3805">Evaluable population (participants treated between 01 September and 01 May of the following year)</participants>
                <participants group_id="P3" count="2248">Evaluable population (participants treated between 01 September and 01 May of the following year)</participants>
                <participants group_id="P4" count="13711">Evaluable population (participants treated between 01 September and 01 May of the following year)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Evaluable population includes participants who received their first palivizumab injection between 01 September and 31 May of a given season, and who were younger than 2 years at start of immunoprophylaxis. For registry 09/10 – 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.</population>
      <group_list>
        <group group_id="B1">
          <title>Palivizumab Registry 02/03 – 06/07</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 to 30 June 2007.</description>
        </group>
        <group group_id="B2">
          <title>Palivizumab Registry 07/08</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
        </group>
        <group group_id="B3">
          <title>Palivizumab Registry 08/09</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2008 to 30 June 2009.</description>
        </group>
        <group group_id="B4">
          <title>Palivizumab Registry 09/10 – 15/16</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10686"/>
            <count group_id="B2" value="3805"/>
            <count group_id="B3" value="2248"/>
            <count group_id="B4" value="12729"/>
            <count group_id="B5" value="29468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Gestational age at birth is reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="29468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 29 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3582"/>
                    <measurement group_id="B2" value="1173"/>
                    <measurement group_id="B3" value="694"/>
                    <measurement group_id="B4" value="3514"/>
                    <measurement group_id="B5" value="8963"/>
                  </measurement_list>
                </category>
                <category>
                  <title>29 to &lt; 33 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3385"/>
                    <measurement group_id="B2" value="1161"/>
                    <measurement group_id="B3" value="705"/>
                    <measurement group_id="B4" value="4033"/>
                    <measurement group_id="B5" value="9284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>33 to ≤ 35 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1500"/>
                    <measurement group_id="B2" value="578"/>
                    <measurement group_id="B3" value="474"/>
                    <measurement group_id="B4" value="3237"/>
                    <measurement group_id="B5" value="5789"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 35 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="375"/>
                    <measurement group_id="B4" value="1945"/>
                    <measurement group_id="B5" value="2965"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1738"/>
                    <measurement group_id="B2" value="729"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="29468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4901"/>
                    <measurement group_id="B2" value="1737"/>
                    <measurement group_id="B3" value="1019"/>
                    <measurement group_id="B4" value="5707"/>
                    <measurement group_id="B5" value="13364"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5716"/>
                    <measurement group_id="B2" value="2051"/>
                    <measurement group_id="B3" value="1229"/>
                    <measurement group_id="B4" value="7013"/>
                    <measurement group_id="B5" value="16009"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="29468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 1000 g</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3283"/>
                    <measurement group_id="B2" value="1101"/>
                    <measurement group_id="B3" value="595"/>
                    <measurement group_id="B4" value="2946"/>
                    <measurement group_id="B5" value="7925"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1000 – 1499 g</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2782"/>
                    <measurement group_id="B2" value="965"/>
                    <measurement group_id="B3" value="538"/>
                    <measurement group_id="B4" value="3063"/>
                    <measurement group_id="B5" value="7348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1500 – 1999 g</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1788"/>
                    <measurement group_id="B2" value="659"/>
                    <measurement group_id="B3" value="424"/>
                    <measurement group_id="B4" value="2590"/>
                    <measurement group_id="B5" value="5461"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 2000 g</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2595"/>
                    <measurement group_id="B2" value="995"/>
                    <measurement group_id="B3" value="691"/>
                    <measurement group_id="B4" value="4130"/>
                    <measurement group_id="B5" value="8411"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Start of Immunoprophylaxis</title>
          <population>Data are reported where available. Data are reported separately for different registry phases as no overall analysis was performed.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Registry 02/03 – 06/07</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10059"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="10059"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="4.0"/>
                    <measurement group_id="B5" value="5.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Registry 07/08</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="3578"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="3578"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="5.0" spread="4.0"/>
                    <measurement group_id="B5" value="5.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Registry 08/09</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="2248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="5.9" spread="4.9"/>
                    <measurement group_id="B5" value="5.9" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Registry 09/10 – 15/16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="12729"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="4.3" spread="3.6"/>
                    <measurement group_id="B5" value="4.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk Factors for RSV Complications</title>
          <population>Data are reported where available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Premature birth (&lt; 29 weeks GA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8948"/>
                    <count group_id="B2" value="3076"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="27001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3582"/>
                    <measurement group_id="B2" value="1173"/>
                    <measurement group_id="B3" value="694"/>
                    <measurement group_id="B4" value="3514"/>
                    <measurement group_id="B5" value="8963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature birth (≤ 35 weeks GA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8948"/>
                    <count group_id="B2" value="3076"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="27001"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8467"/>
                    <measurement group_id="B2" value="2912"/>
                    <measurement group_id="B3" value="1873"/>
                    <measurement group_id="B4" value="10784"/>
                    <measurement group_id="B5" value="24036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple births</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9752"/>
                    <count group_id="B2" value="3771"/>
                    <count group_id="B3" value="2141"/>
                    <count group_id="B4" value="12147"/>
                    <count group_id="B5" value="27811"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2607"/>
                    <measurement group_id="B2" value="922"/>
                    <measurement group_id="B3" value="632"/>
                    <measurement group_id="B4" value="3793"/>
                    <measurement group_id="B5" value="7954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital heart disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9588"/>
                    <count group_id="B2" value="3677"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12544"/>
                    <count group_id="B5" value="28057"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3001"/>
                    <measurement group_id="B2" value="1283"/>
                    <measurement group_id="B3" value="567"/>
                    <measurement group_id="B4" value="3430"/>
                    <measurement group_id="B5" value="8281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking in the family</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8043"/>
                    <count group_id="B2" value="3031"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="6332"/>
                    <count group_id="B5" value="19654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1422"/>
                    <measurement group_id="B2" value="482"/>
                    <measurement group_id="B3" value="400"/>
                    <measurement group_id="B4" value="2037"/>
                    <measurement group_id="B5" value="4341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic lung disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9805"/>
                    <count group_id="B2" value="3501"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12422"/>
                    <count group_id="B5" value="27976"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4179"/>
                    <measurement group_id="B2" value="1330"/>
                    <measurement group_id="B3" value="584"/>
                    <measurement group_id="B4" value="2346"/>
                    <measurement group_id="B5" value="8439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunodeficiency</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8875"/>
                    <count group_id="B2" value="3428"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12271"/>
                    <count group_id="B5" value="26822"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="430"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attending daycare</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9722"/>
                    <count group_id="B2" value="3745"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12389"/>
                    <count group_id="B5" value="28104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="361"/>
                    <measurement group_id="B5" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other children (&lt; 12 years) in household</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9662"/>
                    <count group_id="B2" value="3728"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="10767"/>
                    <count group_id="B5" value="26405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4440"/>
                    <measurement group_id="B2" value="1682"/>
                    <measurement group_id="B3" value="1115"/>
                    <measurement group_id="B4" value="4899"/>
                    <measurement group_id="B5" value="12136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of asthma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7877"/>
                    <count group_id="B2" value="2956"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="10589"/>
                    <count group_id="B5" value="23670"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="823"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="1128"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of allergic rhinitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7819"/>
                    <count group_id="B2" value="2920"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="25716"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1234"/>
                    <measurement group_id="B2" value="450"/>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of allergic eczema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7751"/>
                    <count group_id="B2" value="2889"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="25617"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="713"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of atopy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="10606"/>
                    <count group_id="B5" value="27345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="346"/>
                    <measurement group_id="B4" value="2039"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyanotic heart defect</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12363"/>
                    <count group_id="B5" value="29102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="784"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic lung disease therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12291"/>
                    <count group_id="B5" value="29030"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="281"/>
                    <measurement group_id="B4" value="1803"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment with oxygen at home</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12490"/>
                    <count group_id="B5" value="29229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="763"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuromuscular impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="8435"/>
                    <count group_id="B5" value="25174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="786"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Down syndrome (Trisomy 21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="29468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="249"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious neurological disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="8393"/>
                    <count group_id="B5" value="25132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="428"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low social status</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="11915"/>
                    <count group_id="B5" value="28654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="2258"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crowded living conditions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="10575"/>
                    <count group_id="B5" value="27314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="2592"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposition to air pollution</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="10960"/>
                    <count group_id="B5" value="27699"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="1710"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast feeding ≤ 2 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10686"/>
                    <count group_id="B2" value="3805"/>
                    <count group_id="B3" value="2248"/>
                    <count group_id="B4" value="11417"/>
                    <count group_id="B5" value="28156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B2" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B3" value="NA">This risk factor was not assessed during this period</measurement>
                    <measurement group_id="B4" value="5794"/>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunoprophylaxis with Palivizumab Started in Hospital</title>
          <population>Data are reported where available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10544"/>
                    <count group_id="B2" value="3745"/>
                    <count group_id="B3" value="1798"/>
                    <count group_id="B4" value="12729"/>
                    <count group_id="B5" value="28816"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1645"/>
                    <measurement group_id="B2" value="519"/>
                    <measurement group_id="B3" value="313"/>
                    <measurement group_id="B4" value="3127"/>
                    <measurement group_id="B5" value="5604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With RSV-associated Hospitalization</title>
        <time_frame>During RSV season (September to June) from 2002 to 2016</time_frame>
        <population>Evaluable population with available hospitalization data</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 02/03 – 06/07</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 to 30 June 2007.</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Registry 07/08</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
          </group>
          <group group_id="O3">
            <title>Palivizumab Registry 08/09</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2008 to 30 June 2009.</description>
          </group>
          <group group_id="O4">
            <title>Palivizumab Registry 09/10 – 15/16</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RSV-associated Hospitalization</title>
          <population>Evaluable population with available hospitalization data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9833"/>
                <count group_id="O2" value="3805"/>
                <count group_id="O3" value="2248"/>
                <count group_id="O4" value="12729"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnosis Documented at Hospital Discharge in Registries 02/03 - 06/07 and 07/08</title>
        <description>Hospitalization due to RSV was documented on a separate hospitalization form. The data below represent the number of hospitalizations documented on forms; some participants may have had more than one hospitalization. Multiple entries for discharge diagnosis were possible.</description>
        <time_frame>During RSV season (September to June) from 2002 to 2008</time_frame>
        <population>Participants in registries 02/03 - 06/07 and 07/08 who were hospitalized, and hospitalization was documented on paper case report forms.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 02/03 – 06/07</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 to 30 June 2007.</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Registry 07/08</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnosis Documented at Hospital Discharge in Registries 02/03 - 06/07 and 07/08</title>
          <description>Hospitalization due to RSV was documented on a separate hospitalization form. The data below represent the number of hospitalizations documented on forms; some participants may have had more than one hospitalization. Multiple entries for discharge diagnosis were possible.</description>
          <population>Participants in registries 02/03 - 06/07 and 07/08 who were hospitalized, and hospitalization was documented on paper case report forms.</population>
          <units>hospitalizations</units>
          <param>Count of Units</param>
          <units_analyzed>hospitalizations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>hospitalizations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronchiolitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RSV-Bronchiolitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia (Viral pneumonia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RSV-Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RSV-Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any RSV diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnosis Documented at Hospital Discharge in Registry 08/09 and 09/10 - 15/16</title>
        <description>In the season 2008/09, the eCRF system for data collection was introduced. Hospitalization due to RSV infection was documented on a separate hospitalization form in the electronic case report form (eCRF). Physicians were asked to specify a primary diagnosis at hospital discharge.</description>
        <time_frame>During RSV season (September to June) from 2008 to 2016</time_frame>
        <population>Participants in registries 08/09 and 09/10 – 15/16 who were hospitalized, and hospitalization was documented on forms and with available diagnosis data (for registry 09/10 – 15/16)</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 08/09</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2008 to 30 June 2009.</description>
          </group>
          <group group_id="O2">
            <title>Registry 09/10 – 15/16 Hospitalization Associated With RSV</title>
            <description>Participants who were prescribed palivizumab (Synagis®) prophylaxis according to the German SPC for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016, and had a hospitalization associated with RSV infection.</description>
          </group>
          <group group_id="O3">
            <title>Registry 09/10 – 15/16 Hospitalizations Not RSV-Associated</title>
            <description>Participants who were prescribed palivizumab (Synagis®) prophylaxis according to the German SPC for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016, and had a hospitalization that was not associated with RSV infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnosis Documented at Hospital Discharge in Registry 08/09 and 09/10 - 15/16</title>
          <description>In the season 2008/09, the eCRF system for data collection was introduced. Hospitalization due to RSV infection was documented on a separate hospitalization form in the electronic case report form (eCRF). Physicians were asked to specify a primary diagnosis at hospital discharge.</description>
          <population>Participants in registries 08/09 and 09/10 – 15/16 who were hospitalized, and hospitalization was documented on forms and with available diagnosis data (for registry 09/10 – 15/16)</population>
          <units>hospitalizations</units>
          <param>Count of Units</param>
          <units_analyzed>hospitalizations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>hospitalizations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchiolitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia (clinical diagnosis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia (confirmed by chest radiography)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute respiratory failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apnoea-bradycardia syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Complications During Hospitalization</title>
        <time_frame>During RSV season (September to June) from 2002 to 2016</time_frame>
        <population>Evaluable population who were hospitalized and with available hospitalization complication data</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 02/03 – 06/07</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 until 30 June 2007.</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Registry 07/08</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
          </group>
          <group group_id="O3">
            <title>Palivizumab Registry 08/09</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from
01 September 2008 to 30 June 2009.</description>
          </group>
          <group group_id="O4">
            <title>Registry 09/10 – 15/16 Hospitalization Associated With RSV</title>
            <description>Participants who were prescribed palivizumab (Synagis®) prophylaxis according to the German SPC for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016, and had a hospitalization that was associated with RSV infection.</description>
          </group>
          <group group_id="O5">
            <title>Registry 09/10 – 15/16 Hospitalizations Not RSV-Associated</title>
            <description>Participants who were prescribed palivizumab (Synagis®) prophylaxis according to the German SPC for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016, and had a hospitalization that was not associated with RSV infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Complications During Hospitalization</title>
          <population>Evaluable population who were hospitalized and with available hospitalization complication data</population>
          <units>hospitalizations</units>
          <param>Count of Units</param>
          <units_analyzed>hospitalizations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="269"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>hospitalizations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intensive care unit (ICU) admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="231"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>hospitalizations</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="83"/>
                    <count group_id="O5" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxygen supplementation required</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="265"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>hospitalizations</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical ventilation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="213"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>hospitalizations</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parental Cooperation in Registries 02/03 - 06/07 and 07/08</title>
        <description>Cooperation of parents with the prophylaxis regimen was categorized as very good, good, moderate, bad or very bad.</description>
        <time_frame>During RSV season (September to June) from 2002 to 2008</time_frame>
        <population>Evaluable population in registries 02/03 - 06/07 and 07/08</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 02/03 – 06/07</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 to 30 June 2007.</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Registry 07/08</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
          </group>
        </group_list>
        <measure>
          <title>Parental Cooperation in Registries 02/03 - 06/07 and 07/08</title>
          <description>Cooperation of parents with the prophylaxis regimen was categorized as very good, good, moderate, bad or very bad.</description>
          <population>Evaluable population in registries 02/03 - 06/07 and 07/08</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10686"/>
                <count group_id="O2" value="3805"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very good/good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9383"/>
                    <measurement group_id="O2" value="3340"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="567"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bad/very bad</title>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="382"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parental Cooperation for Registry 08/09 and 09/10 - 15/16</title>
        <description>Cooperation of parents with the prophylaxis regimen was evaluated per injection in registry 08/09 and 09/10 - 15/16. The categories for cooperation ratings were changed to good, satisfying, or bad:
Good: all palivizumab doses could be administered as planned; Satisfying: a single palivizumab dose was missed by the parents; Bad: more than one palivizumab doses was missed by the parents.</description>
        <time_frame>During RSV season (September to June) from 2008 to 2016</time_frame>
        <population>Evaluable population in in registries 08/09 and 09/10 - 15/16; for registry 09/10 - 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 08/09</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2008 to 30 June 2009.</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Registry 09/10 – 15/16</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016.</description>
          </group>
        </group_list>
        <measure>
          <title>Parental Cooperation for Registry 08/09 and 09/10 - 15/16</title>
          <description>Cooperation of parents with the prophylaxis regimen was evaluated per injection in registry 08/09 and 09/10 - 15/16. The categories for cooperation ratings were changed to good, satisfying, or bad:
Good: all palivizumab doses could be administered as planned; Satisfying: a single palivizumab dose was missed by the parents; Bad: more than one palivizumab doses was missed by the parents.</description>
          <population>Evaluable population in in registries 08/09 and 09/10 - 15/16; for registry 09/10 - 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.</population>
          <units>Palivizumab injections</units>
          <param>Count of Units</param>
          <units_analyzed>Palivizumab injections</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2248"/>
                <count group_id="O2" value="12729"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Palivizumab injections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11039"/>
                <count group_id="O2" value="63572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8175"/>
                    <measurement group_id="O2" value="51408"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfying</title>
                  <measurement_list>
                    <measurement group_id="O1" value="550"/>
                    <measurement group_id="O2" value="2985"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bad</title>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="575"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2171"/>
                    <measurement group_id="O2" value="8604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Palivizumab Injections</title>
        <description>The mean number of palivizumab injections per participant, per season.</description>
        <time_frame>During RSV season (September to June) from 2002 to 2016</time_frame>
        <population>Evaluable population; for registry 09/10 - 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab Registry 02/03 – 06/07</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2002 to 30 June 2007.</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Registry 07/08</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2007 to 30 June 2008.</description>
          </group>
          <group group_id="O3">
            <title>Palivizumab Registry 08/09</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2008 to 30 June 2009.</description>
          </group>
          <group group_id="O4">
            <title>Palivizumab Registry 09/10 – 15/16</title>
            <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season from 01 September 2009 to 30 June 2016.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Palivizumab Injections</title>
          <description>The mean number of palivizumab injections per participant, per season.</description>
          <population>Evaluable population; for registry 09/10 - 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.</population>
          <units>palivizumab injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10686"/>
                <count group_id="O2" value="3805"/>
                <count group_id="O3" value="2248"/>
                <count group_id="O4" value="12729"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.8"/>
                    <measurement group_id="O2" value="4.8" spread="1.9"/>
                    <measurement group_id="O3" value="4.9" spread="2.0"/>
                    <measurement group_id="O4" value="5.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During RSV season (June to September) from 2002 to 2016</time_frame>
      <desc>Evaluable population includes participants who received their first palivizumab injection between 01 September and 31 May of a given season, and who were younger than 2 years at start of immunoprophylaxis. For registry 09/10 - 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Palivizumab</title>
          <description>Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season (September to June) from 2002 to 2016.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="701" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>MYOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESTRICTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CONGENITAL CENTRAL HYPOVENTILATION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>FALLOT'S TETRALOGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HEART DISEASE CONGENITAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HYPOPLASTIC LEFT HEART SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LISSENCEPHALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>WOLF-HIRSCHHORN SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>NECROTISING COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ADVERSE EVENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ADENOVIRAL UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>EXANTHEMA SUBITUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ROTAVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFECTIVE PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LARYNGOTRACHEITIS OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>MYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PERTUSSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PSEUDOCROUP</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>SUPERINFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>INJECTION RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANTIMICROBIAL SUSCEPTIBILITY TEST RESISTANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BREATH SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CATHETERISATION CARDIAC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFLUENZA VIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DIET REFUSAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>FLUID INTAKE REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LACTOSE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HAEMANGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HISTIOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFANTILE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>NEONATAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>POOR WEIGHT GAIN NEONATAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>APATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>APPARENT LIFE THREATENING EVENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHIAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HYPERCAPNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFANTILE APNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>IRREGULAR BREATHING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>LARYNGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>NEONATAL HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RALES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA INFANTILE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CARDIAC OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ELECTIVE PROCEDURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ENTEROSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HERNIA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>HOSPITALISATION</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ILEOSTOMY CLOSURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>IMMUNISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>OXYGEN SUPPLEMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL RECONSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PLASTIC SURGERY OF THE LIPS AND MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PULMONARY VALVE REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HEART DISEASE CONGENITAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADMINISTRATION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>ADVERSE EVENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DRUG INEFFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>IRRITABILITY POSTVACCINAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>BRUCELLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>VACCINATION COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DIET REFUSAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>FEEDING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>PERSONALITY CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>SCREAMING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHIAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HOSPITALISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29468"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

